Predicting Objective Response of Pembrolizumab in Platinum-Refractory Urothelial Carcinoma Based on NLR Fluctuation and Liver Metastases

CONCLUSIONS: At the six weeks of the pembrolizumab treatment, our risk model predicts the objective response rate precisely. Notably, those classified as 'poor risk'-marked by liver metastasis and a heightened NLR-should be considered for alternative therapy with a different mode of action, highlighting a critical decision point in treatment optimization.PMID:37839399 | DOI:10.1159/000534554

Source: Oncology - October 15, 2023 Category: Cancer & Oncology Authors: Kyosuke Nishio Takuya Higashio Kazumasa Komura Wataru Fukuokaya Takahiro Adachi Yosuke Hirasawa Takeshi Hashimoto Atsuhiko Yoshizawa Shuya Tsuchida Takuya Matsuda Takuya Tsujino Kazuki Nishimura Satoshi Tokushige Keita Nakamori Taizo Uchimoto Shutaro Yama Source Type: research